The first in-human trial of a CRISPR Cas system delivered by adeno-associated virus 9 gene therapy to treat HIV was able to target only the intended DNA and cleared the blood within 6 months.
Hosted on MSN
CRISPR-based gene editing revolutionized medicine—the company that helped develop it says that's just the beginning
Since its discovery in 2011, CRISPR-Cas 9 has revolutionized medicine. One of the companies at the forefront of this revolution is CRISPR Therapeutics. I’ve been a couples therapist for 30 years: Any ...
CHICAGO, IL—A novel CRISPR/Cas-9-based gene-editing technique seems to safely diminish the production of a protein linked to worsening outcomes in patients with transthyretin (ATTR) amyloidosis ...
SAN DIEGO--(BUSINESS WIRE)--iXCells Biotechnologies (“iXCells” or the “Company”), a provider of cell products and drug discovery services to the worldwide academic, biotech and pharmaceutical ...
**Note: the release below is a special early release from the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024, Barcelona, Spain, 27-30 April). Please credit the ...
The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 gene-editing tool to spiders. Following the genetic modification, the spiders ...
In December 2020, the New England Journal of Medicine published a paper titled CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, marking an exciting new chapter in the treatment of ...
Gene editing in plants remains challenging, with the traditional non-homologous end-joining (cNHEJ) repair pathway often hindering precision. In this study, researchers advanced CRISPR-Cas-based gene ...
Genome editing with various CRISPR-Cas molecule complexes has progressed rapidly in recent years. Hundreds of labs around the world are now working to put these tools to clinical use and are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback